Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes
1998/04/01 by W. Sean Davidson, Ana Jonas, David F. Clayton +1 · 42 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Parkinson's Disease Mechanisms and Treatments #Alzheimer's disease research and treatments #Cellular transport and secretion
paper · doi:10.1074/jbc.273.16.9443
Abstract
alpha-Synuclein is a highly conserved presynaptic protein of unknown function. A mutation in the protein has been causally linked to Parkinson's disease in humans, and the normal protein is an abundant component of the intraneuronal inclusions (Lewy bodies) characteristic of the disease. alpha-Synuclein is also the precursor to an intrinsic component of extracellular plaques in Alzheimer's disease. The alpha-synuclein sequence is largely composed of degenerate 11-residue repeats reminiscent of the amphipathic alpha-helical domains of the exchangeable apolipoproteins. We hypothesized that alpha-synuclein should associate with phospholipid bilayers and that this lipid association should stabilize an alpha-helical secondary structure in the protein. We report that alpha-synuclein binds to small unilamellar phospholipid vesicles containing acidic phospholipids, but not to vesicles with a net neutral charge. We further show that the protein associates preferentially with vesicles of smaller diameter (20-25 nm) as opposed to larger (approximately 125 nm) vesicles. Lipid binding is accompanied by an increase in alpha-helicity from 3% to approximately 80%. These observations are consistent with a role in vesicle function at the presynaptic terminal.
Cited by
- The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation
- Phosphatidic acid in membrane rearrangements
- The Lipid-binding Domain of Wild Type and Mutant α-Synuclein
- Alpha-synuclein, autophagy-lysosomal pathway, and Lewy bodies: Mutations, propagation, aggregation, and the formation of inclusions
- Lipidation as a post-translational code for protein liquid-liquid phase separation
- Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation
- Statins reduce neuronal α‐synuclein aggregation in <i>in vitro</i> models of Parkinson’s disease
- Organic Anion Transporting Polypeptide–Mediated Hepatic Uptake of Glucuronide Metabolites of Androgens
- Non‐classical exocytosis of α‐synuclein is sensitive to folding states and promoted under stress conditions
- Excess phosphoserine-129 α-synuclein induces synaptic vesicle trafficking and declustering defects at a vertebrate synapse
- Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease
- Parkinson's Disease
- Synaptic vesicle architecture modulates α-synuclein conformation and pathogenic transitions in Parkinson’s disease
- Studies on curcumin-glucoside in the prevention of alpha-synuclein aggregation.
- Group II late embryogenesis abundant (LEA) proteins: structural and functional aspects in plant abiotic stress
- In vivo aggregation of presynaptic alpha-synuclein is not influenced by its phosphorylation at serine-129
- Concentration-Dependent Mutational Scanning Probes the Cellular Folding Landscape of <i>α</i> -Synuclein in Yeast
- alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. [europepmc]
- Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. [europepmc]
- Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. [europepmc]
- A role for alpha-synuclein in the regulation of dopamine biosynthesis. [europepmc]
- Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. [europepmc]
- Lipid rafts mediate the synaptic localization of alpha-synuclein. [europepmc]
- Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. [europepmc]
- Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. [europepmc]
- Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. [europepmc]
- In vivo demonstration that alpha-synuclein oligomers are toxic. [europepmc]
- α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. [europepmc]
- Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. [europepmc]
- Properties of native brain α-synuclein. [europepmc]
- The function of α-synuclein. [europepmc]
- α-Synuclein is localized to mitochondria-associated ER membranes. [europepmc]
- Lipid vesicles trigger α-synuclein aggregation by stimulating primary nucleation. [europepmc]
- Nanoparticle Uptake: The Phagocyte Problem. [europepmc]
- α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease. [europepmc]
- Cell Biology and Pathophysiology of α-Synuclein. [europepmc]
- α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. [europepmc]
- α-synuclein in the pathophysiology of Alzheimer's disease. [europepmc]
- Structures of α-synuclein filaments from multiple system atrophy. [europepmc]
- Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. [europepmc]
- Neuropathology and molecular diagnosis of Synucleinopathies. [europepmc]
- Structures of α-synuclein filaments from human brains with Lewy pathology. [europepmc]
Related